BioAge Labs, Inc. BIOA
5.87 USD +0.09 (+1.56%)
At closeNov 11, 2026, 4:00 PM EST
5.64 -0.23 -3.94%
After hours · Nov 11, 4:00 PM ET
5.76 Day range 6.08
4.81 52-week range 25.96
- YTD
- -55.63%
- 1 year
- -25.03%
News
globenewswire.com BioAge Labs to Present at Upcoming Investor Conferences EMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates…
benzinga.com Piper Sandler Maintains Overweight on Bioage Labs, Lowers Price Target to $40 Piper Sandler analyst Yasmeen Rahimi maintains Bioage Labs (NASDAQ:BIOA) with a Overweight and lowers the price target from $73 to $40.
zacks.com BioAge Labs, Inc. (BIOA) Reports Q3 Loss, Misses Revenue Estimates BioAge Labs, Inc. (BIOA) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.56 per share a year ago.
benzinga.com Bioage Labs Q3 EPS $(0.73) Misses $(0.59) Estimate, Sales $298.000K Miss $1.644M Estimate Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.59) by 23.73 percent. This is a 30.36 percent decrease over losses of…
globenewswire.com BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027
benzinga.com BioArctic AB Announces Novartis Terminates Their 2025 Option, Collaboration And License Deal; BioArctic To Retain Full $30M Upfront Payment BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered…
benzinga.com UBS Initiates Coverage On Bioage Labs with Neutral Rating, Announces Price Target of $8 UBS analyst Alice Nettleton initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Neutral rating and announces Price Target of $8.